| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b25376aeaee21b58622a71462d7d10f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e44ddd2b61676511afbb11dfc7c8908e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06b1bdda8e45365b22ac9ef8dafaa90a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_652853e2425401c4f9dc624994296b37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf22712343f6d7dad8177be97f4ff5e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc1e220e857f103caac8da57d6c69269
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ebf2bf6bb29df2dd5e092643fefac7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2250add5c0ba4415743b9332c1d1f8fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ffa04b9fb8d93a056a2a16090c5dbab |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2101-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C271-56 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C271-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-00 |
| filingDate |
2011-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_099934441171ccf0cf4b9c224f846005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea681590f4afd0f6a92d7045f4d69962
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebe1a10491254403a07b8167702ee7ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_954d28c09b03bb3d7b24722201b3ca95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7020d38cd085b83cab850efd03c70a5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da77eb2355acabfb55a78565d37ed75c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b80b269da0e57480371a6263ab75589 |
| publicationDate |
2015-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9187413-B2 |
| titleOfInvention |
Peripherally restricted FAAH inhibitors |
| abstract |
Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R 1 is a polar group. In some embodiments, R 1 is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof. R 2 and R 3 are independently selected from the group consisting of hydrogen and substituted or unsubstituted hydrocarbyl; each R 4 is independently selected from the group consisting of halogen and substituted or unsubstituted hydrocarbyl and n is an integer from 0 to 4; each R 5 is independently selected from the group consisting of halo and substituted or unsubstituted hydrocarbyl and m is an integer from 0 to 3; and R 6 is substituted or unsubstituted cyclohexyl; and the pharmaceutically acceptable salts thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9745255-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10435355-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9822068-B2 |
| priorityDate |
2010-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |